Immune Activation,Inflammation and HIV DNA after 96 Weeks of ATV/r Monotherapy: A MODAt Substudy

Oldenbuettel C. , Wolf E. , Ritter A. Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results. Antivir Ther 2017; 22: 169–172.

Bierman W.F. , van Agtmael M.A. , Nijhuis M. , Danner S.A. , Boucher C.A. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 23: 279–291.

Oddershede L. , Walker S. , Stohr W. Cost effectiveness of protease inhibitor monotherapy versus standard triple therapy in the long-term management of HIV patients: analysis using evidence from the PIVOT Trial. Pharmacoeconomics 2016; 34: 795–804.

Calvez V. , Hocqueloux L. , Meynard J.L. Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why? J Antimicrob Chemother 2017; 72: 19–28.

Baril J.G. , Angel J.B. , Gill M.J. Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-naive or ARV-experienced, virologically suppressed patients. PLoS One 2016; 11: e0148231.

Hunt P.W. , Lee S.A. , Siedner M.J. Immunologic biomarkers, morbidity, and mortality in treated HIV infection. J Infect Dis 2016; 214 Suppl 2: S44–S50.

Cannizzo E.S. , Bellistri G.M. , Casabianca A. Immunophenotype and function of CD38-expressing CD4+ and CD8+ T cells in HIV-infected patients undergoing suppressive combination antiretroviral therapy. J Infect Dis 2015; 211: 1511–1513.

Erlandson K.M. , Campbell T.B. Inflammation in chronic HIV infection: what can we do? J Infect Dis 2015; 212: 339–342.

BenMarzouk-Hidalgo O.J. , Torres-Cornejo A. , Gutierrez-Valencia A. , Ruiz-Valderas R. , Viciana P. , Lopez-Cortes L F. . Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy. Medicine (Baltimore) 2015; 94: e781.

Arenas-Pinto A. , Milinkovic A. , Peppa D. , McKendry A. , Maini M. , Gilson R. Systemic inflammation and residual viraemia in HIV-positive adults on protease inhibitor monotherapy: a cross-sectional study. BMC Infect Dis 2015; 15: 138.

Hileman C.O. , Kinley B. , Scharen-Guivel V. Differential reduction in monocyte activation and vascular inflammation with integrase inhibitor-based initial antiretroviral therapy among HIV-infected individuals. J Infect Dis 2015; 212: 345–354.

Romero-Sanchez M.C. , Alvarez-Rios A.I. , Bernal-Morell E. Maintenance of virologic efficacy and decrease in levels of beta2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy. Antiviral Res 2014; 111: 26–32.

Galli L. , Spagnuolo V. , Bigoloni A. Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. J Antimicrob Chemother 2016; 71: 1637–1642.

Castagna A. , Spagnuolo V. , Galli L. Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results. AIDS 2014; 28: 2269–2279.

Palmer B.E. , Blyveis N. , Fontenot A.P. , Wilson C.C. Functional and phenotypic characterization of CD57+CD4+ T cells and their association with HIV-1-induced T cell dysfunction. J Immunol 2005; 175: 8415–8423.

Pastuszczak M. , Gozdzialska A. , Jakiela B. , Obtulowicz A. , Jaskiewicz J. , Wojas-Pelc A. Robust pro-inflammatory immune response is associated with serological cure in patients with syphilis: an observational study. Sex Transm Infect 2017; 93: 11–14.